Jelly Force Gummies, New disclosure outlines an 82 mg proprietary blend, serving information and the limitations of comparing individual ingredient studies with the finished supplement
PINELLAS PARK, Fla. — October 5, 2026 — JellyForce has published updated ingredient and serving information for its U.S. gummy supplement, providing consumers with a closer look at the product’s Supplement Facts panel and explaining why research involving individual ingredients should not be interpreted as evidence for the finished formula.
According to the current label information, one gummy constitutes one serving, with 30 servings in each container. The Supplement Facts panel lists a proprietary blend totaling 82 milligrams and containing eight ingredients: Muira Puama extract, Maca extract, Catuaba extract, Korean Red Ginseng, Ashwagandha, L-Arginine, Tribulus Terrestris and Epimedium extract.
The label also describes the blend as equivalent to approximately 567 milligrams of dry plant material. That equivalency reflects the use of concentrated extracts rather than indicating that the gummy physically contains 567 milligrams of the listed ingredients.
The company is publishing the specifications to clarify what consumers can and cannot determine from a proprietary-blend label, particularly when reviewing research involving individual botanical or nutritional ingredients.
“The label provides the total weight of the proprietary blend, but it does not provide the amount of each individual ingredient,” said Kevin Moore, Product Head at Jelly Force. “That distinction matters when people encounter studies involving one of the ingredients because the dose, extract and population studied may be very different from the finished product.”
Proprietary Blend Disclosure Limits Ingredient-by-Ingredient Comparison
Under U.S. dietary-supplement labeling rules, a manufacturer may identify a proprietary blend by its combined weight while separately listing the ingredients included in that blend. The amount of every individual component does not necessarily have to appear on the Supplement Facts panel.
For JellyForce, the disclosed total is 82 milligrams per serving across eight ingredients.
Because individual amounts are not provided, the label cannot be used to determine exactly how many milligrams of Ashwagandha, Maca, L-Arginine or any other component are contained in one gummy.
A simple mathematical division of the total blend would produce an average of approximately 10 milligrams per ingredient if all eight ingredients were present in equal quantities. However, the label does not state that the ingredients are distributed evenly, and the calculation should therefore not be treated as an estimate of the actual amount of any particular ingredient.
The same limitation applies to the label’s statement that the extracts are equivalent to about 567 milligrams of dry plant material. Dividing the dry-material equivalent by the 82-milligram extract weight produces an overall ratio of approximately seven to one, but that calculation does not reveal the concentration or extraction ratio of any individual ingredient.
For consumers comparing a supplement label with scientific literature, those distinctions can be significant.
Published Ingredient Research Uses Different Dosages and Formulations
Jelly Force also reviewed several published studies involving ingredients appearing on its label. The research discussed is independent of JellyForce and did not evaluate Jelly Force Gummies.
The company says the purpose of presenting the studies is to establish context rather than to suggest that findings from individual ingredients apply to the finished gummy.
Ashwagandha
A randomized, double-blind, placebo-controlled study published in the Indian Journal of Psychological Medicine in 2012 evaluated 64 adults experiencing chronic stress.
Participants receiving the intervention were given 300 milligrams of a high-concentration Ashwagandha root extract twice daily for 60 days, producing a total daily amount of 600 milligrams.
Researchers reported differences in stress-assessment scores and measured cortisol compared with the placebo group.
The study examined a particular extract at a specific dose and should not be extrapolated to other formulas without considering differences in dosage and composition. The National Center for Complementary and Integrative Health has also stated that evidence regarding Ashwagandha varies by intended use and has identified safety considerations, including reports involving liver injury.
The Jelly Force proprietary blend totals 82 milligrams across all eight ingredients, so the label does not establish that the Ashwagandha amount is comparable to the amount used in that study.
Maca
Research involving Maca also illustrates the difference between ingredient-level studies and proprietary-blend supplements.
A study published in the Journal of Endocrinology evaluated daily Maca quantities of 1,500 milligrams and 3,000 milligrams in healthy adult men. Researchers reported no significant changes in the reproductive hormone levels examined during the study.
Those quantities refer specifically to the Maca preparation evaluated by the researchers.
Because JellyForce discloses only the combined weight of its eight-ingredient blend, the amount of Maca in a serving cannot be determined from the label and cannot be directly compared with the study doses.
Korean Red Ginseng
A systematic review published in the Journal of Alternative and Complementary Medicine examined research related to ginseng and fatigue.
The review characterized the evidence as limited and inconsistent across the studies evaluated.
The National Center for Complementary and Integrative Health has similarly noted that Asian ginseng products can differ considerably in composition and that research findings vary depending on the health outcome being examined.
As with other botanical extracts, differences in formulation, extraction method, dose, study duration and participant characteristics can make direct comparisons between products difficult.
L-Arginine
L-Arginine has been examined in a variety of research settings, with many clinical studies using quantities measured in grams rather than milligrams.
A randomized clinical trial published in JAMA in 2006 studied L-Arginine supplementation in people following myocardial infarction. The treatment did not improve the vascular measures evaluated, and the study was stopped after researchers observed a mortality imbalance between the study groups.
That research does not establish the effects of the much smaller, undisclosed amount that may appear within an 82-milligram multi-ingredient blend. It does, however, demonstrate why ingredient research should be considered in its original clinical context rather than presented as generalized evidence of benefit.
People with cardiovascular conditions or those taking medication should discuss dietary-supplement use with an appropriate healthcare professional.
Tribulus Terrestris
An eight-week study published in the International Journal of Sport Nutrition and Exercise Metabolism evaluated Tribulus terrestris in resistance-trained men.
Researchers reported no significant advantage over placebo in the body-composition or exercise-performance measures examined.
The study involved a specific preparation and study population and did not evaluate JellyForce or a comparable eight-ingredient gummy.
Other Botanical Ingredients
The current JellyForce label also lists Muira Puama extract, Catuaba extract and Epimedium extract.
The company is not presenting human clinical studies for those ingredients in this announcement because it says available evidence is not sufficient to establish findings relevant to its finished formulation.
Ingredient Studies Do Not Establish Finished-Product Results
The distinction between ingredient research and finished-product evidence is central to the company’s latest disclosure.
A study involving a single botanical ingredient does not establish that a multi-ingredient formulation containing that ingredient will produce the same findings.
Variables may include the amount consumed, extraction method, chemical standardization, duration of use, other ingredients in the formulation, participant characteristics and the outcome being measured.
Jelly Force states that no clinical trial has evaluated the finished JellyForce Gummies formulation.
Accordingly, the company is not presenting the cited research as evidence that its gummy produces the outcomes examined in the individual studies.
The publication of ingredient research alongside a product specification should instead allow readers to identify where comparisons are possible and where information remains unavailable.
Consumers Should Distinguish Label Information From Online Descriptions
JellyForce also advises consumers to separate information appearing on the physical Supplement Facts panel from descriptions appearing on third-party websites, reviews or other online sources.
Ingredient lists, serving information and product descriptions found online may become outdated when formulations or packaging change.
For that reason, the current physical package should be treated as the primary source for serving size, ingredients, directions and warnings associated with a particular product.
This distinction is especially important when consumers encounter older reviews or web pages describing different ingredient counts or formulations.
The U.S. Food and Drug Administration does not approve dietary supplements for safety or effectiveness before they enter the market in the same manner used for approved pharmaceutical drugs.
References to manufacturing facilities following Good Manufacturing Practice requirements or being registered with the FDA should also not be interpreted as meaning a dietary supplement itself has received FDA approval.
Jelly Force states that its product is manufactured in the United States using globally sourced ingredients in a facility the company says follows Good Manufacturing Practices.
Health and Medication Considerations
The company says adults considering the product should review the full label and discuss supplement use with a qualified healthcare professional when relevant.
This is particularly important for people who take prescription medication, use multiple supplements or manage an existing medical condition. Ingredients appearing in botanical and amino-acid supplements may interact with medicines or may not be appropriate for certain individuals.
Consumers using blood-pressure medicines, nitrates, blood thinners, diabetes medications, thyroid medications, sedatives or immune-suppressing medicines should discuss supplement use with a healthcare professional. People with heart or liver conditions and those preparing for surgery should also seek individualized medical guidance rather than relying on general product descriptions or ingredient research.
The product is not intended for people under 18. The company also advises people who are pregnant or nursing to consult a healthcare professional before using dietary supplements.
Consumers using more than one dietary supplement should review ingredient lists across all products because the same botanical, vitamin, mineral or other component may appear in multiple formulations.
Label Transparency as a Consumer-Information Issue
The latest JellyForce publication highlights a broader issue affecting interpretation of proprietary-blend supplements: consumers may know which ingredients are present without knowing the individual amount of each ingredient.
That makes comparison with scientific research inherently limited.
For example, knowing that an ingredient appears in both a clinical study and a commercial supplement does not establish that the ingredient is present in a comparable quantity or form.
The 82-milligram blend total provides a defined specification for the JellyForce formulation, but it does not permit ingredient-by-ingredient dose calculations.
The company says readers evaluating Jelly Force Gummies reviews, research summaries or other online discussions should therefore distinguish between verified label information, findings from independent studies and claims made by third parties.
Scientific findings involving one ingredient should remain attributed to the research in which they were observed rather than transferred to the finished gummy.
About Jelly Force
JellyForce distributes dietary supplements in the United States through Info Wealth CO. The current JellyForce Gummies label identifies one gummy as a serving and lists an 82-milligram proprietary blend containing eight botanical and nutritional ingredients.
The product is manufactured in the United States using globally sourced ingredients, according to the company.
Jelly Force states that its current product label and Supplement Facts panel should be used as the primary source for ingredient, serving and usage information.
Media Contact
Kevin Moore
Product Head, JellyForce
11870, 62nd St N, Largo, FL 33773
Email: contact@Jellyforce.online
Website: jelly-force.net
References
Chandrasekhar K, et al. A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of Ashwagandha root in reducing stress and anxiety in adults. Indian Journal of Psychological Medicine, 2012.
National Center for Complementary and Integrative Health. Ashwagandha: Usefulness and Safety.
Gonzales GF, et al. Research examining Lepidium meyenii (Maca) and reproductive hormone levels in healthy adult men. Journal of Endocrinology, 2003.
Arring NM, et al. Ginseng as a treatment for fatigue: a systematic review. Journal of Alternative and Complementary Medicine, 2018.
National Center for Complementary and Integrative Health. Asian Ginseng: Usefulness and Safety.
Schulman SP, et al. L-arginine therapy in acute myocardial infarction: The VINTAGE MI randomized clinical trial. JAMA, 2006.
Antonio J, et al. Research examining Tribulus terrestris in resistance-trained men. International Journal of Sport Nutrition and Exercise Metabolism, 2000.
U.S. Food and Drug Administration. Dietary Supplement Labeling Guide.
Disclaimer: Research involving individual ingredients does not establish the safety or effectiveness of the finished JellyForce Gummies formulation. JellyForce states that no clinical trial has evaluated the finished product. Dietary supplements are not intended to diagnose, treat, cure or prevent disease. Consumers should review the current product label and consult an appropriate healthcare professional when medical guidance is needed.
